Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Proteomics International Laboratories EV-to-Revenue?
Proteomics International LaboratoriesPIQLF 14 EV-to-Revenue is 71.44 as of Sep. 08, 2026, which is 87% above its 10-year median of 38.30. GuruFocus rates PIQLF with a GF Scoreâ„¢ of 14/100 and a GF Valueâ„¢ of $0.19 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 961 Biotechnology companies, Proteomics International Laboratories ranks worse than 66.39% on this metric.
PIQLF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.62 Med: 38.3 Max: 192.76
Current: 19.49
During the past 12 years, the highest EV-to-Revenue of Proteomics International Laboratories was 192.76. The lowest was 3.62. And the median was 38.30.
PIQLF's EV-to-Revenue is ranked worse than 66.39% of 961
companies
in the Biotechnology industry
Industry Median: 9.11
vs PIQLF: 19.49
Proteomics International Laboratories's share price for today is $0.1248.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2026 was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories EV-to-Revenue Related Terms
Proteomics International Laboratories EV-to-Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories EV-to-Revenue Chart
PIQLF vs VRTX, REGN, MRNA: EV-to-Revenue Comparison
For the Biotechnology subindustry, Proteomics International Laboratories's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories EV-to-Revenue vs Biotechnology Industry
Proteomics International Laboratories's current Enterprise Value is $12.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Proteomics International Laboratories's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $0.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories (PIQLF) has a EV-to-Revenue of 71.44 as of Sep. 08, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Proteomics International Laboratories and its competitors. This is 87% above median its historical median of 38.30. Over the past decade, Proteomics International Laboratories' EV-to-Revenue has ranged from 3.62 to 192.76. According to the industry distribution chart, Proteomics International Laboratories ranks #638 out of 961 companies in the Biotechnology industry, placing it in the top 66.4%.
Is Proteomics International Laboratories' EV-to-Revenue too high?
Proteomics International Laboratories' current EV-to-Revenue of 71.44 is 87% above median its 10-year median of 38.30. Over the past 10 years, this metric has ranged from a low of 3.62 to a high of 192.76. The Biotechnology industry median EV-to-Revenue is 9.11. Proteomics International Laboratories' value of 71.44 is 684.2% above this industry median. Based on the distribution chart, Proteomics International Laboratories ranks #638 out of 961 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Proteomics International Laboratories has a GF Scoreâ„¢ of 14/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' EV-to-Revenue compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #638 out of 961 companies for EV-to-Revenue. This places Proteomics International Laboratories in the lower half of its industry. The industry median EV-to-Revenue is 9.11. Proteomics International Laboratories' value of 71.44 is 684.2% above this benchmark. Historically, Proteomics International Laboratories' own EV-to-Revenue has ranged from 3.62 to 192.76 over the past decade. While the company's 10-year median is 38.30 vs. the industry median of 9.11, Proteomics International Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Biotechnology company?
The median EV-to-Revenue among Biotechnology companies is 9.11, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteomics International Laboratories's current EV-to-Revenue of 71.44 is 684.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Proteomics International Laboratories and its competitors. For the Biotechnology industry, the median EV-to-Revenue is 9.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current EV-to-Revenue is 71.44, which is 87% above median its own 10-year median of 38.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Proteomics International Laboratories (PIQLF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.12 — trading 34.3% below its estimated fair value. The current EV-to-Revenue is 71.44, which is 87% above median its 10-year median of 38.30 and 684.2% above the Biotechnology industry median of 9.11. Proteomics International Laboratories' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Proteomics International Laboratories (PIQLF), the current EV-to-Revenue is 71.44 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (PIQLF) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of $0.12 is trading 34.3% below its estimated GF Value™ of $0.19.
GuruFocus considers Proteomics International Laboratories to be Possible Value Trap.
Key valuation signals for PIQLF:
EV-to-Revenue: 71.44 (87% above median its 10-year median of 38.30)
GF Value™: $0.19 vs. price of $0.12 (34.3% below fair value)
Industry Position: 684.2% above the Biotechnology median (#638 of 961)
No single metric tells the full story. See the PIQLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
14GF Score
Get the complete analysis for PIQLF
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PIQLF has been successfully added to your 
